23rd Annual Prostate Cancer Foundation Scientific Retreat

October 27 - 29, 2016

La Costa Resort
Carlsbad, California
AGENDA
Thursday, October 27, 2016

GENERAL SESSIONS
Location: Costa Del Sol Ballroom

8:00 am Registration Costa Del Sol Foyer

Welcome & Introduction
1:30 PM - 1:40 PM
Howard Soule, PhD
Prostate Cancer Foundation

Session 1: New Treatments in Prostate Cancer
1:40 PM - 3:00 PM
Moderator: Joshua Lang, MD
University of Wisconsin Carbone Cancer Center

1:40 PM - 1:55 PM Biomarker-Driven Contexts of Use for a TROP2 Antibody-Drug Conjugate in Prostate Cancer
Joshua Lang, MD
University of Wisconsin Carbone Cancer Center

1:55 PM - 2:00 PM Discussion

2:00 PM - 2:15 PM Understanding PREX2 and PTEN in Cancer
Ramon Parsons, MD, PhD
Icahn School of Medicine at Mount Sinai

2:15 PM - 2:20 PM Discussion

2:20 PM - 2:35 PM IRE1 Signaling Drives Prostate Cancer
Fahri Saatcioglu, PhD
University of Oslo

2:35 PM - 2:40 PM Discussion
2:40 PM - 2:55 PM  *ROR-y Nuclear Receptor as a New Therapeutic Target in Advanced CRPC*
Hongwu Chen, PhD
University of California, Davis

2:55 PM - 3:00 PM  Discussion

**Session 2: Prostate Cancer Research in the Netherlands**

3:00 PM - 4:00 PM  
**Moderators:**
Guido Jenster, PhD
Erasmus Medical Centre, The Netherlands

Jack Schalken, PhD
Radboud University Medical Centre, The Netherlands

3:00 PM - 3:15 PM  *Prostate Cancer Grading Beyond Gleason Score: 3D, Molecular and Clinical Perspective*
Arno van Leenders, MD, PhD
Erasmus Medical Centre, The Netherlands

3:15 PM - 3:20 PM  Discussion

3:20 PM - 3:35 PM  *Epigenetics in Prostate Cancer: From Prognostication to Tailored Therapy*
Wilbert Zwart, PhD
Netherlands Cancer Institute, The Netherlands

3:35 PM - 3:40 PM  Discussion

3:40 PM - 3:55 PM  *Identifying Factors Governing Androgen Therapy Resistance Through Transdifferentiation, an Organoid Approach*
Wouter Karthaus, PhD
Memorial Sloan Kettering Cancer Center

3:55 PM - 4:00 PM  Discussion

**Session 3: Radium for CRPC**

4:00 PM - 5:20 PM  
**Moderator:**
James Gulley, MD, PhD
National Cancer Institute

4:00 PM - 4:15 PM  *Radium-223: Is Bone Targeted Therapy Meeting its Full Potential?*
Michael Morris, MD
Memorial Sloan Kettering Cancer Center

4:15 PM - 4:20 PM  Discussion
Thursday, October 27, 2016

4:20 PM - 4:35 PM  *Radiation Induced Immunogenic Modulation: Insights for Combination Therapy*  
James Gulley, MD, PhD  
National Cancer Institute

4:35 PM - 4:40 PM  Discussion

4:40 PM - 4:55 PM  *Targeting the Bone Compartment in Metastatic Prostate Cancer*  
Nora Navone, MD, PhD  
The University of Texas MD Anderson Cancer Center

4:55 PM - 5:00 PM  Discussion

5:00 PM - 5:15 PM  *Radium-223: A Novel Approach to Prevention and Early Treatment of Bone Metastases from Prostate Cancer*  
Robert Coleman, MD  
University of Sheffield, UK

5:15 PM - 5:20 PM  Discussion

---

**Session 4: Cancer Immunotherapy: Overcoming T Cell Exhaustion in the Tumor Microenvironment**  
5:20 PM - 7:40 PM

Moderator: William Redmond, PhD  
Providence Portland Medical Center

5:20 PM - 5:35 PM  *Immune Suppression in the Tumor Microenvironment of Pancreatic Cancer*  
Sunil Hingorani, MD, PhD  
Fred Hutchinson Cancer Research Center

5:35 PM - 5:40 PM  Discussion

5:40 PM - 5:55 PM  *DNA Repair, the Immune Response and Therapeutic Strategies*  
Johann de Bono, MD, PhD  
Royal Marsden Hospital, UK

5:55 PM - 6:00 PM  Discussion

6:00 PM - 6:15 PM  *Overcoming T-cell Exhaustion in Prostate Cancer*  
Haydn Kissick, PhD  
Emory University School of Medicine

6:15 PM - 6:20 PM  Discussion

6:20 PM - 6:35 PM  *PD-1 Blockade in Prostate Cancer*  
Julie Graff, MD  
Oregon Health & Science University

6:35 PM - 6:40 PM  Discussion
Thursday, October 27, 2016

6:40 PM - 6:55 PM  
**MMR Mutations and Microsatellite Instability in Prostate Cancer**  
Colin Pritchard, MD, PhD  
University of Washington

6:55 PM - 7:00 PM  
Discussion

7:00 PM - 7:15 PM  
**DNA Damage Histological Score & Checkpoint Immunotherapy**  
Mark Linch, MD, PhD  
University College London, UK

7:15 PM - 7:20 PM  
Discussion

7:20 PM - 7:35 PM  
**Novel Immunotherapy Strategies in Prostate Cancer**  
Sumit Subudhi, MD, PhD  
The University of Texas MD Anderson Cancer Center

7:35 PM - 7:40 PM  
Discussion

---

**Dinner**  
7:40 PM - 8:30 PM  

*Dinner Location: Costa Del Sol Patio*

**Poster Session and Dessert**  
8:30 PM - 11:00 PM  

*Poster Session and Dessert Location: Costa Del Sol ABC*
6:30 AM - 7:30 AM  Breakfast
Location: Costa Del Sol Patio

7:30 AM - 7:45 AM  Move to Session

GENERAL SESSIONS
Location: Costa Del Sol Ballroom

Panel Discussion:

Precision Clinicopathologic Conference (CPC):
Hype vs. Hope vs. Hypothesis
7:45 AM - 8:45 AM

Moderator: Johann de Bono, MD, PhD
Royal Marsden Hospital, UK

Felix Feng, MD (University of California, San Francisco)
Maha Hussain, MD (Northwestern University)
Christopher Logothetis, MD (University of Texas MD Anderson Cancer Center)
Silke Gillessen, MD (Kantonsspital, Switzerland)
William Nelson, MD, PhD (Johns Hopkins School of Medicine)
Todd Morgan, MD (University of Michigan)
Scott Tomlins, MD, PhD (University of Michigan)

8:45 AM - 8:50 AM  Break

Session 5: Immunotherapy for Prostate Cancer
8:50 AM - 10:10 AM
Moderator: Howard Soule, PhD
Prostate Cancer Foundation
Friday, October 28, 2016

8:50 AM - 9:05 AM  **Targeting Escape from the NKG2D Pathway with a Novel Cancer Vaccine**  
Kai Wucherpfennig, MD, PhD  
Dana-Farber Cancer Institute

9:05 AM - 9:10 AM  **Discussion**

9:10 AM - 9:25 AM  **Improving PSMA Specific Eradication of Metastatic Prostate Cancer Using TGFβ Resistant CAR T Cells**  
Christopher Kloss, PhD  
University of Pennsylvania

9:25 AM - 9:30 AM  **Discussion**

9:30 AM - 9:45 AM  **CAR T Cells for Treatment of Solid Tumors**  
Saul Priceman, PhD  
City of Hope

9:45 AM - 9:50 AM  **Discussion**

9:50 AM - 10:05 AM  **Marrow Infiltrating Lymphocytes: Their Biology and Clinical Implications**  
Ivan Borrello, MD  
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

10:05 AM - 10:10 AM  **Discussion**

---

**SPECIAL LECTURE**

10:10 AM - 10:50 AM

**State of the Science 2016**

Jonathan Simons, MD  
Prostate Cancer Foundation

*Introduced by Howard Soule, PhD  
Prostate Cancer Foundation*

10:50 AM - 10:55 AM  **Discussion**
KEYNOTE ADDRESS
10:55 AM - 11:55 AM

Michael Milken
Founder and Chairman
Prostate Cancer Foundation

Introduced by Stuart Holden, MD
Prostate Cancer Foundation

Group Photo
11:55 AM - 12:10 PM

Location: TBD

Lunch
12:10 PM - 1:05 PM

Location: Costa Del Sol Patio

1:05 PM - 1:15 PM  Move to Session 6

Location: Costa Del Sol Ballroom

Session 6: Targeting DNA Repair Deficiency in Prostate Cancer
1:15 PM - 3:10 PM

Moderator: Bruce Montgomery, MD
University of Washington

1:15 PM - 1:45 PM  Special Lecture: Targeting DNA Repair in Cancer Therapy
Alan D’Andrea, MD
Harvard Medical School

1:45 PM - 1:50 PM  Discussion
1:50 PM - 2:05 PM  PARP Inhibitors: Opportunities and Challenges in Prostate Cancer
Joaquin Mateo, MD
The Institute of Cancer Research, UK

2:05 PM - 2:10 PM  Discussion

2:10 PM - 2:25 PM  Loss of DNA Repair in Prostate Cancer, Lessons from Breast and Ovarian Cancer
Richard Kennedy, MD, PhD
Queen's University Belfast

2:25 PM - 2:30 PM  Discussion

2:30 PM - 2:45 PM  Platinum Agents in Homologous Recombination Deficiency
Bruce Montgomery, MD
University of Washington
Mark Pomerantz, MD
Dana-Farber Cancer Institute

2:45 PM - 2:50 PM  Discussion

2:50 PM - 3:05 PM  Aggressive Variant Prostate Cancers: Clinical and Molecular Characterization
Ana Aparicio, MD
The University of Texas MD Anderson Cancer Center

3:05 PM - 3:10 PM  Discussion

Session 7: Targeting Developmental Pathways in Prostate Cancer
3:10 PM - 4:50 PM
Moderator: Carlos Moreno, PhD
Winship Cancer Institute at Emory University

3:10 PM - 3:25 PM  Fundamentals of Canonical and Non-Canonical WNT Signaling in Cancer
Stuart Aaronson, MD
Mount Sinai Hospital

3:25 PM - 3:30 PM  Discussion

3:30 PM - 3:45 PM  Notch Signaling Promotes Prostate Cancer Metastasis
Li Xin, PhD
Baylor College of Medicine

3:45 PM - 3:50 PM  Discussion

3:50 PM - 4:05 PM  Molecular Signatures in Circulating Prostate Cancer Cells
Daniel Haber, MD, PhD
Massachusetts General Hospital Cancer Center

4:05 PM - 4:10 PM  Discussion
4:10 PM - 4:25 PM  
SOX4 in PI3K/AKT and WNT Signaling in Prostate Cancer  
Carlos Moreno, PhD  
Winship Cancer Institute at Emory University

4:25 PM - 4:30 PM  
Discussion

4:30 PM - 4:45 PM  
Pharmacologically Targeting WNT Signals in Cancer Stem Cells  
Michael Kahn, PhD  
University of Southern California

4:45 PM - 4:50 PM  
Discussion

Special Announcement  
4:50 PM - 5:00 PM

PyL Molecular Imaging Clinical Investigation

Mark Baker, JD  
Progenics Pharmaceuticals
**Dinner, Awards Ceremony, and Special Lecture**

**7:15 PM - 10:00 PM**

*Location: Costa Del Sol Ballroom*

**Special Lecture:**

*Genomic-Based Medicine and the Impact on Cancer*

**8:15 PM - 8:35 PM**

**J. Craig Venter, PhD**

Human Longevity, Inc.

*Introduced by:*

Michael Milken

Prostate Cancer Foundation

**PCF Awards Ceremony**

**8:45 PM - 9:30 PM**

*Featuring:*

**PCF Career Recognition Award**

**Gary Gallick, PhD**

University of Texas MD Anderson Cancer Center

*Presented by:*

Nora Navone, MD

University of Texas MD Anderson Cancer Center

Christopher Logothetis, MD

University of Texas MD Anderson Cancer Center
Saturday, October 29, 2016

6:30 AM - 7:30 AM  Breakfast  
Location: Costa Del Sol Patio

7:30 AM - 7:45 AM  Move to Session 8

GENERAL SESSIONS  
Location: Costa Del Sol Ballroom

Session 8: New Platforms to Attack the Undruggable Targets  
7:45 AM - 9:50 AM
Moderator: Marco Gottardis, PhD  
Janssen Research & Development, LLC

7:45 AM - 7:50 AM  Introduction  
Marco Gottardis, PhD  
Janssen Research & Development, LLC

7:50 AM - 8:05 AM  NK cells and Prostate Cancer  
David Raulet, PhD  
University of California, Berkeley

8:05 AM - 8:10 AM  Discussion

8:10 AM - 8:25 AM  Targeting Recalcitrant Cancer Drivers using Cell-Penetrating Miniproteins  
Gregory Verdine, PhD  
Fog Pharmaceuticals, Inc.

8:25 AM - 8:30 AM  Discussion

8:30 AM - 8:45 AM  PROTACs: Making the Problem Go Away via Induced Protein Degradation  
Craig Crews, PhD  
Yale University

8:45 AM - 8:50 AM  Discussion

8:50 AM - 9:05 AM  Drugging the Spliceosome: Therapeutic Modulation of Splicing in Human Malignancies  
Markus Warmuth, MD  
H3 Biomedicine, Inc.

9:05 AM - 9:10 AM  Discussion
9:10 AM - 9:25 AM  Development of a Pyrrole-Imidazole Polyamide for Treatment of Enzalutamide Resistant Prostate Cancer
Nickolas Nickols, PhD, MD
David Geffen School of Medicine at UCLA

9:25 AM - 9:30 AM  Discussion

9:30 AM - 9:45 AM  Expression Studies Implicate Neuroendocrine Prostate Cancer as a Novel Indication for Rovalpituzumab Tesirine – A Delta-Like Protein 3 (DLL3)-Targeted Antibody-Drug Conjugate (ADC)
Laura Saunders, PhD
StemCentrx, Inc.

9:45 AM - 9:50 AM  Discussion

Session 9: Precision Survivorship
9:50 AM - 11:05 AM

Moderators:
Alicia Morgans, MD, MPH
Vanderbilt University Medical Center
Charles Ryan, MD
University of California, San Francisco

9:50 AM - 9:55 AM  Introduction
Alicia Morgans, MD, MPH
Vanderbilt University Medical Center

9:55 AM - 10:10 AM  Cardiovascular Perils of Prostate Cancer Survivorship: A Personalized Approach to Prevention
Javid Moslehi, MD, PhD
Vanderbilt University Medical Center

10:10 AM - 10:15 AM  Discussion

10:15 AM - 10:30 AM  ADT and the Brain: The Unwanted Target
Charles Ryan, MD
University of California, San Francisco

10:30 AM - 10:35 AM  Discussion

10:35 AM - 11:00 AM  Special Lecture: On the Etiologies of Dementing Diseases Caused by Prions
Stanley Prusiner, MD
University of California, San Francisco

11:00 AM - 11:05 AM  Discussion
Saturday, October 29, 2016

Session 10: Circulating Tumor DNA: A Model for Public-Private Partnership
11:05 AM - 12:10 PM
Moderator: Gerhardt Attard, MD, PhD
The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, UK

11:05 AM - 11:10 AM Introduction
Gerhardt Attard, MD, PhD
The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, UK

11:10 AM - 11:25 AM Quantification of Circulating Tumor DNA
Francesca Demichelis, PhD
University of Trento, Italy

11:25 AM - 11:30 AM Discussion

11:30 AM - 11:45 AM Circulating Tumor DNA and Clinical Outcomes in mCPRC Patients Commencing AR-Targeted Therapy
Alexander Wyatt, PhD
Vancouver Prostate Centre

11:45 AM - 11:50 AM Discussion

11:50 AM - 12:05 PM Early Cancer Detection with Cell-Free Nucleic Acids: Challenges and Opportunities for Prostate Cancer
Mark Lee, MD, PhD
GRAIL, Inc.

12:05 PM - 12:10 PM Discussion

Closing Remarks
12:10 PM - 12:15 PM
Howard Soule, PhD
Prostate Cancer Foundation
Jonathan Simons, MD
Prostate Cancer Foundation

Meeting Adjourned
** A boxed lunch will be provided **
Program Committee:

Program Committee Co-Chair: Howard Soule, PhD (Prostate Cancer Foundation)
Program Committee Co-Chair: Andrea Miyahira, PhD (Prostate Cancer Foundation)

Jonathan Simons, MD (Prostate Cancer Foundation)
Gerhardt Attard, MD, PhD (The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, UK)
Johann de Bono, MD, PhD (Royal Marsden Hospital, UK)
Marco Gottardis, PhD (Janssen Research & Development, LLC)
James Gulley, MD, PhD (National Cancer Institute)
Guido Jenster, PhD (Erasmus Medical Centre, The Netherlands)
Joshua Lang, MD (University of Wisconsin Carbone Cancer Center)
Bruce Montgomery, MD (University of Washington)
Carlos Moreno, PhD (Winship Cancer Institute at Emory University)
Alicia Morgans, MD, MPH (Vanderbilt University Medical Center)
William Redmond, PhD (Providence Portland Medical Center)
Charles Ryan, MD (University of California, San Francisco)
Jack Schalken, PhD (Radboud University Medical Centre, The Netherlands)
We deeply thank our Retreat supporters for providing funding for this educational initiative.